Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
Human respiratory syncytial virus (RSV) and parainfluenza virus type 3 (HPIV3) are among the most common viral causes of childhood bronchiolitis and pneumonia worldwide, and lack effective antiviral drugs or vaccines. Recombinant (r) HPIV3 was modified to express the RSV fusion (F) glycoprotein, the...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0228572 |
id |
doaj-5f5445bd5a834a39a953e5141230cfd8 |
---|---|
record_format |
Article |
spelling |
doaj-5f5445bd5a834a39a953e5141230cfd82021-03-03T21:29:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01152e022857210.1371/journal.pone.0228572Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.Xueqiao LiuBo LiangXiang LiuEmerito Amaro-CarambotSonja SurmanPeter D KwongBarney S GrahamPeter L CollinsShirin MunirHuman respiratory syncytial virus (RSV) and parainfluenza virus type 3 (HPIV3) are among the most common viral causes of childhood bronchiolitis and pneumonia worldwide, and lack effective antiviral drugs or vaccines. Recombinant (r) HPIV3 was modified to express the RSV fusion (F) glycoprotein, the major RSV neutralization and protective antigen, providing a live intranasal bivalent HPIV3/RSV vaccine candidate. This extends previous studies using a chimeric bovine-human PIV3 vector (rB/HPIV3). One advantage is that rHPIV3 expresses all of the HPIV3 antigens compared to only two for rB/HPIV3. In addition, the use of rHPIV3 as vector should avoid excessive attenuation following addition of the modified RSV F gene, which may occur with rB/HPIV3. To enhance its immunogenicity, RSV F was modified (i) to increase the stability of the prefusion (pre-F) conformation and (ii) by replacement of its transmembrane (TM) and cytoplasmic tail (CT) domains with those of HPIV3 F (H3TMCT) to increase incorporation in the vector virion. RSV F (+/- H3TMCT) was expressed from the first (F/preN) or the second (F/N-P) gene position of rHPIV3. The H3TMCT modification dramatically increased packaging of RSV F into the vector virion and, in hamsters, resulted in significant increases in the titer of high-quality serum RSV-neutralizing antibodies, in addition to the increase conferred by pre-F stabilization. Only F-H3TMCT/preN replication was significantly attenuated in the nasal turbinates by the RSV F insert. F-H3TMCT/preN, F/N-P, and F-H3TMCT/N-P provided complete protection against wt RSV challenge. F-H3TMCT/N-P exhibited the most stable and highest expression of RSV F, providing impetus for its further development.https://doi.org/10.1371/journal.pone.0228572 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xueqiao Liu Bo Liang Xiang Liu Emerito Amaro-Carambot Sonja Surman Peter D Kwong Barney S Graham Peter L Collins Shirin Munir |
spellingShingle |
Xueqiao Liu Bo Liang Xiang Liu Emerito Amaro-Carambot Sonja Surman Peter D Kwong Barney S Graham Peter L Collins Shirin Munir Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. PLoS ONE |
author_facet |
Xueqiao Liu Bo Liang Xiang Liu Emerito Amaro-Carambot Sonja Surman Peter D Kwong Barney S Graham Peter L Collins Shirin Munir |
author_sort |
Xueqiao Liu |
title |
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. |
title_short |
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. |
title_full |
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. |
title_fullStr |
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. |
title_full_unstemmed |
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. |
title_sort |
human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion f protein modified for virion packaging yields protective intranasal vaccine candidates. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2020-01-01 |
description |
Human respiratory syncytial virus (RSV) and parainfluenza virus type 3 (HPIV3) are among the most common viral causes of childhood bronchiolitis and pneumonia worldwide, and lack effective antiviral drugs or vaccines. Recombinant (r) HPIV3 was modified to express the RSV fusion (F) glycoprotein, the major RSV neutralization and protective antigen, providing a live intranasal bivalent HPIV3/RSV vaccine candidate. This extends previous studies using a chimeric bovine-human PIV3 vector (rB/HPIV3). One advantage is that rHPIV3 expresses all of the HPIV3 antigens compared to only two for rB/HPIV3. In addition, the use of rHPIV3 as vector should avoid excessive attenuation following addition of the modified RSV F gene, which may occur with rB/HPIV3. To enhance its immunogenicity, RSV F was modified (i) to increase the stability of the prefusion (pre-F) conformation and (ii) by replacement of its transmembrane (TM) and cytoplasmic tail (CT) domains with those of HPIV3 F (H3TMCT) to increase incorporation in the vector virion. RSV F (+/- H3TMCT) was expressed from the first (F/preN) or the second (F/N-P) gene position of rHPIV3. The H3TMCT modification dramatically increased packaging of RSV F into the vector virion and, in hamsters, resulted in significant increases in the titer of high-quality serum RSV-neutralizing antibodies, in addition to the increase conferred by pre-F stabilization. Only F-H3TMCT/preN replication was significantly attenuated in the nasal turbinates by the RSV F insert. F-H3TMCT/preN, F/N-P, and F-H3TMCT/N-P provided complete protection against wt RSV challenge. F-H3TMCT/N-P exhibited the most stable and highest expression of RSV F, providing impetus for its further development. |
url |
https://doi.org/10.1371/journal.pone.0228572 |
work_keys_str_mv |
AT xueqiaoliu humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates AT boliang humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates AT xiangliu humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates AT emeritoamarocarambot humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates AT sonjasurman humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates AT peterdkwong humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates AT barneysgraham humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates AT peterlcollins humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates AT shirinmunir humanparainfluenzavirustype3expressingtherespiratorysyncytialvirusprefusionfproteinmodifiedforvirionpackagingyieldsprotectiveintranasalvaccinecandidates |
_version_ |
1714816614830964736 |